Key result
Gene delivery of BAG3 via rAAV9 improved left ventricular function in mice with left ventricular dysfunction secondary to a myocardial infarction.
Why the study?
Does rAAV9-BAG3 gene delivery improve cardiac performance in mice with post-MI left ventricular dysfunction?
RCT
randomly assigned
Does rAAV9-BAG3 gene delivery improve cardiac performance in mice with post-MI left ventricular dysfunction?
BAG3 gene therapy via rAAV9 vector improves left ventricular function in a murine model of post-MI heart failure, suggesting a potential novel therapeutic approach.
BAG3 gene delivery may enhance post-MI cardiac performance in mice; leaves open translation to human LV dysfunction.
OBJECTIVES: The present study was undertaken to test the hypothesis that gene delivery of BCL2-Associated Athanogene 3 (BAG3) to the heart of mice with left ventricular dysfunction secondary to a myocardial infarction could enhance cardiac performance. BACKGROUND: BAG3 is a 575 amino acid protein that has pleotropic functions in the cell including pro-autophagy and anti-apoptosis. Mutations in BAG3 have been associated with both skeletal muscle dysfunction and familial dilated cardiomyopathy and BAG3 levels are diminished in non-familial heart failure. METHODS: Eight-week-old C57/BL6 mice underwent ligation of the left coronary artery (MI) or sham surgery (Sham). Eight weeks later, mice in both groups were randomly assigned to receive either a retro-orbital injection of rAAV9-BAG3 (MI-BAG3 or Sham-BAG3) or rAAV9-GFP (MI-GFP or Sham GFP). Mice were sacrificed at 3 weeks post-injection and myocytes were isolated from the left ventricle. RESULTS: amplitude. IMPLICATIONS: The results suggest that BAG3 gene therapy may provide a novel therapeutic option for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Knezevic et al. (2016) conducted an RCT in left ventricular dysfunction secondary to a myocardial infarction. rAAV9-BAG3 vs. rAAV9-GFP was evaluated on left ventricular function. Gene delivery of BAG3 via rAAV9 improved left ventricular function in mice with left ventricular dysfunction secondary to a myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: